Xeris Biopharma Holdings（NASDAQ: XERS）報告季度每股虧損$0.03，優於分析師預期的$0.06，增幅爲50%。相比去年同期每股虧損$0.10，本季度虧損減少了70%。公司報告季度銷售額爲$60.10M，優於分析師預期的$58.10M，增幅爲3.43%。相比去年同期的$44.39M，本季度銷售額增長了35.39%。

以上內容來自Benzinga Earnings專欄，原文如下：

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 70 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $60.10 million which beat the analyst consensus estimate of $58.10 million by 3.43 percent. This is a 35.39 percent increase over sales of $44.39 million the same period last year.